Small deep value individual investor, with a modest private investment portfolio, split approx. 50%-50% between shares and call options. I have a B.Sc. in aeronautical engineering and over 6 years of experience as an engineering consultant in the aerospace sector. The latter statement is not relevant in any way whatsoever to my investment style, but I thought to add it for self-indulgent purposes. I have a contrarian investment style, highly risky, and often dealing with illiquid options. How illiquid? Well ...

The oil giant is once again at the centre of government plans for economic growth and job creation. But Petrobras has a chequered past, including damaging corruption scandals and debt. Critics say it should stick to high-value oil production rather than expanding into refining and shipbuilding #petrobras #brazil #oil #brazilpolitics #brazileconomy #brazilsociety #oilproduction #corruption #companies #scandal 00:00 - Introduction 00:54 - How important is Petrobras? 01:41 - Petrobras and the Brazilian economy ...

Core Insights - The article highlights the increasing recognition among U.S. pharmaceutical insiders of China's innovative drug sector reaching a "DeepSeek moment," where U.S. companies are investing heavily in Chinese new drugs as a strategic bet on their potential [1][5] - The competitive advantage of Chinese innovation still hinges on breakthroughs in core innovation, despite the current advantages in cost and efficiency [1][4] Group 1: Investment Trends - Pfizer acquired overseas rights for a PD-1/VEGF dual antibody from 3SBio for over $6 billion, including an upfront payment of $1.25 billion [1] - Bristol-Myers Squibb secured co-development rights for a similar drug from BioNTech for $11.1 billion, with an upfront payment of $1.5 billion [1] - Chinese companies have sold overseas rights for innovative drugs to U.S. firms, with total commitments nearing $30 billion [3][12] Group 2: Competitive Landscape - There are currently 35 PD-1/VEGF dual antibodies in development globally, with 20 originating from China, indicating a strong clinical advancement from Chinese firms [2] - Chinese companies have evolved from being five years behind in PD-1 monoclonal antibodies to being approximately three years ahead in the dual antibody space [3] Group 3: Research and Development Efficiency - Chinese firms are leveraging engineering optimization as a competitive advantage, combining different monoclonal antibodies and small molecules to create innovative therapies [4] - The cost and speed advantages of Chinese teams in drug development are significant, with estimates suggesting 2-3 times lower costs and about double the speed compared to U.S. teams [6] Group 4: Market Dynamics - In Q1 of this year, 37% of innovative drug transactions with upfront payments over $50 million originated from Chinese companies, nearly doubling from two years ago [7] - Chinese companies now account for 67% of global transactions in oncology, 60% in cardiovascular diseases, and 50% in endocrine and autoimmune diseases [7] Group 5: Future Outlook - The trend of Chinese innovation in pharmaceuticals is expected to continue expanding into other therapeutic areas, with increasing competition anticipated between Chinese and U.S. firms [10] - The "DeepSeek moment" in Chinese biopharmaceuticals is raising awareness among U.S. markets, prompting significant acquisitions and strategic partnerships [10][12]

I won't sugarcoat it. Super Micro Computer, Inc. aka SuperMicro (NASDAQ: SMCI ) has baggage. We’re talking about missed targets, shaky management credibility, customer delays, and even some tariff overhang! These are real concerns, no doubt.Strong Investment PotentialMy Marketplace highlights a portfolio of undervalued investment opportunities - stocks with rapid growth potential, driven by top quality management, while these stocks are cheaply valued.I follow countless companies and select for you the most ...

策 略 研 究 华福证券 突破、主升形态为主 团队成员 投资要点： 策 略 定 期 报 告 主题投资数据库旨在筛选优秀量价形态的主题机会，把握热门主题的 见顶节奏、龙头股的调整程度。在 3/9 发布的《主题投资的下半场决胜法 则》中，我们构建了主题投资的数据追踪体系。我们专注于 2 方面：1）4 种形态量化筛选，高赔率的主题机会；2）构建交易热度指标，把握热门主 题的见顶节奏，并最新增加了龙头股的调整程度观察。后续，我们将定期 更新主题投资数据体系。我们希望通过这种偏量化的方式，给予投资者更 客观的参考，把握住主题投资的行情节奏。 突破、主升形态为主。本期走出见底、突破、主升、加速的主题指数 数量分别有 0、27、20、2 只。其中，27 只突破形态的主题指数中，行业 多为国防军工（6 只）和有色金属（5 只）。20 只主升形态的主题指数中 包含医药生物行业（8 只）和计算机行业（7 只），而 2 只加速形态的主题 指数分别属于交通运输行业、环保行业。 人形机器人、Deepseek 主题的交易热度持续下降，对应龙头股收盘价 仍低于 MA60 的位置。我们对人形机器人、Deepseek 主题进行交易热度的 监控 ...

Group 1 - The "Love Delivery Exam" public welfare initiative was launched in Changsha, aiming to provide comprehensive support for students during the exam period, including traffic management and emergency services [1][2] - The theme for this year's initiative is "High-Five Youth, Let AI Escort," emphasizing the use of AI technology for citywide traffic coordination during the exam period [2][4] - Various departments, including traffic police and public transport, will utilize AI systems to monitor traffic conditions, optimize public transport schedules, and ensure smooth transportation for students [2][4] Group 2 - The "Love Delivery Rainbow Alliance" will implement a series of supportive measures for students, including issuing "Green Passes" for smooth passage of vehicles transporting students [5][6] - Free public transport services will be provided for students with examination permits, including free rides on buses and subways during the exam days [6][7] - Special services for disabled students and their families will be offered, including tailored transportation assistance [7]

Investment Rating - The investment rating for the industry is optimistic [1][2] Core Insights - The capital market is undergoing comprehensive reforms to deepen investment and financing, with a focus on attracting long-term funds [15][27] - The introduction of DeepSeek has driven a strong rise in Chinese technology stocks, significantly impacting market sentiment and performance [27][85] - The overall performance of listed securities firms has improved, with substantial increases in revenue and net profit [16][22] Performance Review of Listed Securities Firms - As of Q1 2025, the total assets of 42 listed securities firms reached 13.11 trillion yuan, an increase of 850 billion yuan from the end of 2024 [16] - The combined operating income for Q1 2025 was 125.93 billion yuan, a year-on-year increase of 19%, while net profit rose by 74.93% to 53.46 billion yuan [16] - The top five firms by operating income were CITIC Securities, Guotai Junan, Huatai Securities, China Galaxy, and GF Securities [16] Industry Development Trends - The securities industry is experiencing a significant increase in revenue concentration, with the CR5 for operating income at 41.74% and for net profit at 54.06% as of Q1 2025 [22] - The number of securities practitioners has decreased by 5.83% year-on-year, indicating a trend towards cost reduction and efficiency improvement [32] - The management expense ratio for listed securities firms decreased to 47.01%, down 3.48 percentage points year-on-year [32] Business Line Performance - Brokerage business saw a significant increase in income, with net income from brokerage fees rising by 43.16% year-on-year to 32.736 billion yuan [38] - The asset management business faced challenges, with net income declining by 3.32% year-on-year to 10.131 billion yuan [45] - The proprietary trading business reported a 51.02% increase in income, totaling 48.566 billion yuan, driven by a recovering equity market [56] Investment Recommendations - The report suggests that the securities sector is poised for a positive outlook due to economic recovery, liquidity easing, and improving performance metrics [91] - The valuation of the brokerage sector is currently at a PB of 1.25X, indicating potential for valuation recovery [91]

Gorilla Technology (NASDAQ: GRRR ), a two-decade old entity that leverages AI, edge computing, and deep learning, to provide technology solutions for clients around various industries (mainly government, logistics, transport, retail, hospitality, etc.) around the globe (although its servicing roots areAnalyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article mys ...

Gold prices are somewhat off their all-time high from mid-April, and interest in talking about gold has waned a bit since we’re not constantly testing new highs. Nevertheless, the price today is still higher than the record highs we were seeingI’m Jason Ditz and I have 20 years of experience in foreign policy research. My work has appeared in Forbes, Toronto Star, Minneapolis Star-Tribune, Providence Journal, Washington Times and the Detroit Free Press, as well as American Conservative Magazine and the Quin ...

Group 1 - The article focuses on the Asia Value & Moat Stocks research service, which targets value investors looking for Asia-listed stocks with significant discrepancies between price and intrinsic value [1] - The service emphasizes deep value balance sheet bargains, such as net cash stocks and low price-to-book (P/B) stocks, as well as wide moat stocks that represent high-quality businesses [1] - The author provides a range of watch lists with monthly updates, particularly concentrating on investment opportunities in the Hong Kong market [1]